Literature DB >> 2848904

Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection.

D E Willey1, E M Cantin, L R Hill, B Moss, A L Notkins, H Openshaw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2848904     DOI： 10.1093/infdis/158.6.1382

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  6 in total

1.  Deletion of the carboxy-terminus of herpes simplex virus type 1 (HSV-1) glycoprotein B does not affect oligomerization, heparin-binding activity, or its ability to protect against HSV challenge.

Authors:  X H Lin; M A Ali; H Openshaw; E M Cantin
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

2.  An intranasal heat shock protein based vaccination strategy confers protection against mucosal challenge with herpes simplex virus.

Authors:  Christopher D Pack; Malgorzata Gierynska; Barry T Rouse
Journal:  Hum Vaccin       Date:  2008-09-28

3.  A vaccinia virus--herpes simplex virus (HSV) glycoprotein B1 recombinant or an HSV vaccine overcome the HSV type 2 induced humoral immunosuppression and protect against vaginal challenge in BALB/c mice.

Authors:  M Fleck; J Podlech; K Weise; D Falke
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

4.  Expression of the Marek's disease virus (MDV) homolog of glycoprotein B of herpes simplex virus by a recombinant baculovirus and its identification as the B antigen (gp100, gp60, gp49) of MDV.

Authors:  M Niikura; Y Matsuura; D Endoh; M Onuma; T Mikami
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

5.  Vaccination with murid herpesvirus-4 glycoprotein B reduces viral lytic replication but does not induce detectable virion neutralization.

Authors:  Janet S May; Philip G Stevenson
Journal:  J Gen Virol       Date:  2010-06-02       Impact factor: 3.891

Review 6.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.